NY-CURIA
13.7.2021 13:32:05 CEST | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005391/en/
Integrity Bio is known in the biopharmaceutical industry as experts in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled its manufacturing capacity. Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.
Integrity Bio’s biologic capabilities are complementary with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
About Integrity Bio
Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries. The organization is known for overcoming challenges associated with biologic formulations and for accommodating unique manufacturing requirements for preclinical and clinical development. For more information, please visit IntegrityBio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM to Drive AI-Powered Modernization of IT Infrastructure and Application Support for UK-based SSP Group26.5.2026 11:00:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has entered a strategic partnership with SSP Group, a leading operator of food and beverage outlets in travel locations worldwide. Through this AI-powered partnership, LTM will deliver modernized, end-to-end IT infrastructure support and enhanced application maintenance services to SSP Group. As part of this engagement, LTM will leverage its advanced AI capabilities including its BlueVerseTM ecosystem to help SSP manage operational risks, simplify infrastructure and application complexities, and drive business efficiency and agility. Additionally, the collaboration will focus on enabling data-driven decision-making, accelerating innovation through automation, delivering scalable solutions that enhance customer experience, and driving cost optimization through AI automation and simplification. “As we continue to advance our IT capabilities, having a trusted partner like LTM with deep domain expertise and a focus on
ROYC and Stilla Enter Strategic Partnership to Operationalise Agentic AI in Private Markets26.5.2026 10:30:00 CEST | Press release
ROYC today announced a partnership with Stilla.ai as the platform layer where ROYC will create, share and run its internally developed AI skills and agents. This operationalises the agentic AI strategy ROYC set out earlier, equipping every function across the company with the tools and resources to build and deploy their own AI agents and converting this into measurable productivity gains and accelerated product development. This will substantially accelerate launch of new platform features, improving cost efficiency at the same time as strengthening overall governance and oversight. For ROYC’s customers and partners, the result will be shorter time-to-market for new product releases, shorter time frames moving from idea to productification and tailored customer experience from an investor services perspective. “Our strategy is clear: AI is embedded in every aspect of our ways of working and what the ROYC Operating System does, not a side project,” said Peter Bergenwald, CTO of ROYC. “
IQOS One of the Most Valuable Global Brands, According to Kantar’s BrandZ 2026 Ranking26.5.2026 10:00:00 CEST | Press release
Recognition reinforces the growing consumer relevance of IQOS and the strength of Philip Morris International’s smoke-free vision Philip Morris International’s (PMI) (NYSE: PM) IQOS, the #1 tobacco heating system1, has been listed for the first time as one of the top 100 most valuable brands in the world in Kantar’s BrandZ 2026 Most Valuable Global Brands. This ranking solidifies IQOS’s global momentum and its emergence as a culturally relevant, iconic brand for adult nicotine users seeking better alternatives to cigarettes. According to the BrandZ 2026 Most Valuable Global Brands, IQOS achieved a ranking of #74 globally. With more than 35 million IQOS users worldwide—most of whom have fully switched away from cigarettes2—the brand continues to lead from the front and champion in a smoke-free era through science-backed innovation and consumer-centric design. Within 10 years of inception, IQOS surpassed $10 billion in annual net revenues, reaching this milestone faster than some of the
Quectel Expands EMEA Reach With Future Electronics Distribution Agreement26.5.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced an expanded distribution partnership with Future Electronics to bring its full portfolio of products and services to customers across the EMEA region. Under this agreement, Future Electronics will bring Quectel’s full IoT portfolio to customers across Europe, the Middle East and Africa, with a strong focus on its non-cellular solutions, including antennas, GNSS, Wi-Fi, Bluetooth and smart modules. This collaboration marks a significant step in strengthening Quectel’s presence in EMEA, leveraging Future Electronics’ strong regional infrastructure, technical expertise, and established customer relationships to accelerate growth and innovation. “Future Electronics’ extensive footprint and demand creation capabilities make them an ideal partner for expanding our reach across EMEA,” said Natasha Barrios, Senior Vice President, EMEA, Quectel Wireless Solutions. “By working together, we can ensure faster a
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom